ACTRIMS 2022 | The challenges of screening and diagnosing multiple sclerosis
Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, discusses the uncertainties surrounding screening and subsequent diagnosis for prodromal multiple sclerosis (MS). Due to the rarity of the disease and non-specific nature of prodromal symptoms, implementing an MS screening program may not be feasible. Prof. Giovannoni therefore emphasizes the importance of educating primary care physicians on the symptoms of MS to enable recognition of prodromal and classic MS events. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
Disclosures
In the last 5 years, Gavin Giovannoni has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, BMS-Celgene, GlaxoSmithKline, GW Pharma, Janssens/Actelion, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Merck KGaA/EMD Serono, Novartis, Sanofi-Genzyme, Roche/Genentech and Teva.
